SkyePharma's Flutiform positive in final Phase III trial
This article was originally published in Scrip
Executive Summary
Preliminary results show that SkyePharma's asthma combination product Flutiform (fluticasone plus formoterol) was positive in its final Phase III trial, clearing the path for a planned EU filing in the first quarter of 2010.